Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.
The user experienced sexual side effects from finasteride and switched to using only topical minoxidil without side effects. They are seeking alternatives to finasteride, such as topical finasteride, to maintain hair without adverse effects.
An experiment to determine the effectiveness of Pyrilutamide in reducing hair loss, using a regimen of Minoxidil and Finasteride, with promising results. The conversation also suggests comparing this to RU58841 as an alternative.
A 29-year-old shared a 6-month update on using 5% topical minoxidil and occasional dermarolling, reporting improved hair density and a fuller crown. They are considering adding finasteride to their routine but are concerned about side effects.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
A 19-year-old male has been using minoxidil 5% and dermarolling for four months to treat hair loss, applying minoxidil twice daily and dermarolling once a week. Commenters suggest consistent treatment, improving picture quality, and adding a 5-alpha-reductase inhibitor to enhance results.
Minoxidil can cause dark circles and skin issues, and users suggest reducing dosage or switching to foam. Supplements like vitamin C, glycine, and MSM may help with collagen production to reduce these side effects.
A user developed a rash after 3 years of using Kirkland minoxidil foam, possibly due to a change in ingredients. They are considering switching to Foligain or Rogaine foam to avoid further issues.
The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.
The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.
A user shared their positive experience with hair regrowth after six months of using minoxidil and finasteride, reporting no side effects. They showed progress photos and expressed hope for full restoration of their hair.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
The conversation discusses hair loss treatments, specifically using a Dermaroller, Minoxidil, and RU58841 for two months. The user shared progress pictures showing the results of these treatments.
User has been using topical Minoxidil (5%) and Finasteride (0.1%) for 5-6 months, along with a dermaroller. No side effects reported, but user notes weight gain without change in diet or exercise.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.
A 24 year old male with no family history of balding who has been using minoxidil foam and Redensyl liquid for two months to treat hair loss, posting pictures to document his progress.
The conversation discusses hair regrowth using RU58841 and Minoxidil in the morning, and Minoxidil with needle massage in the evening. The user is inquiring if there are signs of hair regrowth by comparing photos from September 3 to recent ones.
A user has been using a new brand of minoxidil called VIOFAIRY for six months and finds it effective, though the labeling has misspellings. They are seeking feedback from others who have tried this brand.
The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.
The post and conversation are about a user's progress in treating hair loss using oral finasteride and topical minoxidil. The user expresses regret for not starting treatment earlier.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
The user reported using Morr-F (topical finasteride and minoxidil), microneedling, castor and coconut oil, rosemary oil, and various supplements. They observed some hair regrowth, particularly fine hair on the crown and hairline, after four months of needling and three weeks of Morr-F.
Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.
The conversation discusses the effectiveness of topical tretinoin as a monotherapy for hair loss, with users suggesting it may not be as effective as minoxidil or finasteride. The original poster is considering other options like a phenol peel and is concerned about the risks of derma rolling.
A 21-year-old experiencing itchy and burning scalp with hair loss was diagnosed with MPB and scalp inflammation. They were prescribed Ketoconazole, Prednisone, Clindamycin, and Finasteride, and are considering trying antihistamines, dietary changes, and "nopoo" to alleviate symptoms.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.